Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biofrontera (BFRI) Other Non Operating Income: 2020-2025

Historic Other Non Operating Income for Biofrontera (BFRI) over the last 5 years, with Sep 2025 value amounting to $30,000.

  • Biofrontera's Other Non Operating Income rose 193.75% to $30,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$365,000, marking a year-over-year increase of 24.27%. This contributed to the annual value of -$316,000 for FY2024, which is 321.33% down from last year.
  • Biofrontera's Other Non Operating Income amounted to $30,000 in Q3 2025, which was up 111.36% from -$264,000 recorded in Q2 2025.
  • In the past 5 years, Biofrontera's Other Non Operating Income ranged from a high of $270,000 in Q4 2021 and a low of -$316,000 during Q1 2024.
  • Over the past 3 years, Biofrontera's median Other Non Operating Income value was -$32,500 (recorded in 2023), while the average stood at -$75,100.
  • The largest annual percentage gain for Biofrontera's Other Non Operating Income in the last 5 years was 259.09% (2023), contrasted with its biggest fall of 4,766.67% (2023).
  • Biofrontera's Other Non Operating Income (Quarterly) stood at $270,000 in 2021, then slumped by 98.89% to $3,000 in 2022, then slumped by 4,766.67% to -$140,000 in 2023, then tumbled by 191.43% to -$32,000 in 2024, then skyrocketed by 193.75% to $30,000 in 2025.
  • Its Other Non Operating Income was $30,000 in Q3 2025, compared to -$264,000 in Q2 2025 and -$99,000 in Q1 2025.